查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403517

至 2030 年掌腱膜挛缩症市场预测：按疾病类型、治疗、诊断、给药途径、分销管道、最终用户和地区进行的全球分析

Dupuytren Disease Market Forecasts to 2030 - Global Analysis By Disease Type, Treatment, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球掌腱膜挛缩症市场规模为 44 亿美元，预计到 2030 年将达到 68.6 亿美元，预测期内复合年增长率为 6.6%。

掌腱膜挛缩症，也称为Dupuytren氏挛缩，是一种影响手部和手指的疾病。其特征是手掌皮肤下的结缔组织增厚和硬化。掌腱膜挛缩症的主要特征是在手掌上形成结节或肿块，这些结节或肿块可能会发展成组织索，将受影响的手指向内拉。

发病率增加

随着世界人口老化，受掌腱膜挛缩症影响的人数自然也增加，特别是在该病患病率较高的地区。此外，认识的提高和诊断能力的提高有助于更准确、及时地识别掌腱膜挛缩症患者。总体而言，掌腱膜挛缩症的盛行率上升为改善患者照护和新治疗方法的市场开拓创造了机会，从而推动了市场成长。

治疗费用高

治疗成本是掌腱膜挛缩症市场的一个重要抑制因素，影响了需求。切除术和筋膜切开术等手术介入以及某些药物治疗涉及大量费用，包括住院费用、外科医生费用和术后护理。此外，掌腱膜挛缩症有復发的可能性，需要额外的治疗并随着时间的推移增加患者的总费用。

治疗方法的创新

治疗方案的技术创新是掌腱膜挛缩症市场的关键驱动力，加速了需求。胶原蛋白酶注射剂的引入彻底改变了掌腱膜挛缩症的治疗方法。胶原酶是一种分解收缩组织的酶，使受影响的手指伸直。这种非手术方法避免了切口和麻醉的需要，为患者提供了一种侵入性较小的治疗选择。

治疗选择有限

掌腱膜挛缩症在患者之间表现出很大的异质性，其严重程度、受影响的手腕关节和治疗反应各不相同。这种变异性使得预测治疗结果和为每个人选择最合适的治疗变得困难。在某些患者中，儘管经过治疗，挛缩的改善可能有限或復发，需要额外的干预措施或合併治疗方法。因此，掌腱膜挛缩症市场的治疗选择有限，对市场成长构成挑战。

COVID-19 的影响

COVID-19 的爆发对双相疾病市场产生了重大影响，带来了影响患者照护和市场动态的挑战。医疗保健系统优先分配资源来应对这一流行病，扰乱了常规医疗服务并延迟了掌腱膜挛缩症的诊断和治疗。此外，疫情期间的供应链中断和製造挑战正在影响 Dupuytren 独特治疗方法的可用性和分销。

预计放射线治疗将成为预测期内最大的部门

预计放射线治疗领域将占最大份额。放射线治疗使用高能量辐射来瞄准和抑制与掌腱膜挛缩症相关的异常组织生长。这种非侵入性治疗方法特别适用于疾病晚期的患者，其特征是出现影响手部功能的挛缩和结节。当多个手指受到影响或手术后復发时尤其有效。

预计注射剂领域在预测期内复合年增长率最高。

预计肠外给药领域在预测期内将出现良好的成长。在掌腱膜挛缩症中，肠胃外给药途径在绕过胃肠道直接向患者体内提供治疗性介入方面发挥着至关重要的作用。这种直接方法可确保治疗药物的快速吸收和分布，从而在疾病症状管理中发挥最佳功效。此外，肠胃外途径最大限度地降低了药物在胃肠道环境中降解和改变的风险，从而提高了生物有效性。

比最大的地区

在估计期间，北美占据了最大的市场占有率。该地区拥有先进的医疗基础设施、完善的法律规范以及掌腱膜挛缩症的高盛行率，尤其是在人口老化地区。该地区的医疗保健环境鼓励采用先进的外科手术、注射治疗和非侵入性选择。此外，该地区的研究机构、製药公司和医疗保健提供者之间的合作正在促进新治疗方法的开发。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现盈利成长。该地区发生了重大转变，采用了先进的医疗技术和治疗方法掌腱膜挛缩症的方法。不断增加的研究倡议、区域和国际医疗保健营业单位之间的合作以及不断发展的医疗保健政策都有助于创新治疗方法的开发和采用。该地区的市场开拓进一步受到经济发展、医疗成本降低以及更注重以患者为中心的护理的推动。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球掌腱膜挛缩症市场：依疾病类型

  • Ⅰ型
  • II型
  • Ⅲ型

第六章全球掌腱膜挛缩症市场：依治疗分类

  • 针腱膜切开术
  • 外科手术
  • 酵素注射液
  • 放射治疗
  • 类固醇注射
  • 职能治疗
  • 其他治疗

第七章全球掌腱膜挛缩症市场：依诊断

  • X射线
  • 体检
  • 其他诊断

第八章全球掌腱膜挛缩症市场：依给药途径

  • 胃肠外的
  • 口服
  • 其他给药途径

第九章全球掌腱膜挛缩症市场：按分销管道

  • 网路药房
  • 零售药房
  • 其他分销管道

第 10 章 全球掌腱膜挛缩症市场：依最终使用者分类

  • 诊所
  • 医院
  • 学术研究所

第十一章全球掌腱膜挛缩症市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Pfizer Inc
  • AstraZeneca
  • Endo International plc
  • LEO Pharma A/S
  • Spear Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Bristol-Meyers Squibb Company
  • Fresenius Kabi AG
  • GSK plc
  • Actiza Pharmaceutical Private Limited
  • Nantong Jinghua Pharmaceutical Co., Ltd
  • Novartis AG
  • Bayer AG.
  • Johnson & Johnson Services Ltd.
  • Aurobindo Pharma
Product Code: SMRC24742

According to Stratistics MRC, the Global Dupuytren Disease Market is accounted for $4.40 billion in 2023 and is expected to reach $6.86 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dupuytren's disease, also known as Dupuytren's contracture, is a medical condition that affects the hands and fingers. It is characterized by the thickening and tightening of the connective tissue beneath the skin in the palm of the hand. The primary feature of Dupuytren's disease is the development of nodules or lumps in the palm, which may progress to form cords of tissue that pull the affected fingers inward.

Market Dynamics:

Driver:

Increasing incidence

As the global population ages, particularly in regions with a higher prevalence of this condition, there is a natural rise in the number of individuals affected by Dupuytren's disease. Moreover, heightened awareness and improved diagnostic capabilities contribute to the more accurate and timely identification of Dupuytren's disease cases. Overall, the escalating incidence of Dupuytren's disease propels market growth by creating opportunities for improved patient care and the development of novel treatment modalities.

Restraint:

High cost of treatment

The cost of treatment serves as a notable restraint in the Dupuytren's disease market, impacting the demand. Surgical interventions, such as fasciectomy or fasciotomy, and certain pharmaceutical treatments involve substantial costs; include hospitalization, surgeon fees, and post-operative care. Moreover, the potential for recurrence in Dupuytren's disease necessitates additional treatments, amplifying the overall cost for patients over time.

Opportunity:

Technological innovations in treatment options

Technological innovations in treatment options are a significant driver in the Dupuytren disease market, accelerating the demand. The introduction of collagenase injections has revolutionized the treatment of Dupuytren disease. Collagenase is an enzyme that can break down the contracted tissue, enabling the straightening of the affected fingers. This non-surgical approach avoids the need for incisions or anaesthesia and provides patients with a less-invasive treatment option.

Threat:

Limited treatment options

Dupuytren disease exhibits significant heterogeneity among patients, with variations in disease severity, affected hand joints, and response to treatments. This variability makes it challenging to predict treatment outcomes and select the most appropriate intervention for each individual. Some patients may experience limited improvement or recurrence of contractures even after undergoing treatment, leading to the need for additional interventions or a combination of treatment approaches. Therefore, the limited treatment options in the dupuytren disease market pose a challenge to market growth.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Dupuytren disease market, introducing challenges that have influenced both patient care and market dynamics. The healthcare system's prioritization of resources toward managing the pandemic has led to disruptions in routine medical services, delaying the diagnosis and treatment of Dupuytren disease. Additionally, supply chain disruptions and manufacturing challenges during the pandemic have affected the availability and distribution of Dupuytren-specific treatments.

The radiation therapy segment is expected to be the largest during the forecast period

The radiation therapy segment is estimated to hold the largest share. Radiation therapy involves the use of high-energy radiation to target and reduce abnormal tissue growth associated with Dupuytren's disease. This non-invasive treatment modality is particularly considered for individuals with advanced stages of the disease, characterized by contractures and nodules impacting hand function. It is especially beneficial in cases where multiple fingers are affected or when the disease recurs after surgery.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have lucrative growth during the forecast period. In Dupuytren's disease the parenteral route of administration plays a pivotal role in delivering therapeutic interventions directly into the patient's system, bypassing the gastrointestinal tract. This direct approach ensures rapid absorption and distribution of the therapeutic agent, allowing for optimal efficacy in managing the disease's symptoms. Moreover, the parenteral route minimizes the risk of degradation or alteration of the drug in the gastrointestinal environment, enhancing its bioavailability.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The region comprises advanced healthcare infrastructure, a well-established regulatory framework, and a high prevalence of Dupuytren's disease, particularly in the aging population. The region's healthcare landscape encourages the adoption of advanced surgical procedures, injectable treatments, and non-invasive options. Moreover, collaborations between research institutions, pharmaceutical companies, and healthcare providers contribute to the development of novel therapies in this region.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. In this region, there is a notable shift toward embracing advanced medical technologies and therapies for Dupuytren's disease. Increased research initiatives, collaborations between regional and international healthcare entities, and evolving healthcare policies contribute to the development and adoption of innovative treatment options. The market's growth in this region is further propelled by economic development, improved healthcare affordability, and a heightened focus on patient-centric care.

Key players in the market:

Some of the key players in the Dupuytren Disease Market include Pfizer Inc, AstraZeneca, Endo International plc, LEO Pharma A/S, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Meyers Squibb Company, Fresenius Kabi AG, GSK plc, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd, Novartis AG, Bayer AG., Johnson & Johnson Services Ltd. and Aurobindo Pharma.

Key Developments:

In August 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

Disease Types Covered:

  • Type I
  • Type II
  • Type III

Treatments Covered:

  • Needle Aponeurotomy
  • Surgery
  • Enzyme Injection
  • Radiation Therapy
  • Steroid Shot
  • Occupational Therapy
  • Other Treatments

Diagnosis Covered:

  • X-Ray
  • Physical Examination
  • Other Diagnosis

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Other Route of Administrations

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

End Users Covered:

  • Clinics
  • Hospitals
  • Academic & Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dupuytren Disease Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Type I
  • 5.3 Type II
  • 5.4 Type III

6 Global Dupuytren Disease Market, By Treatment

  • 6.1 Introduction
  • 6.2 Needle Aponeurotomy
  • 6.3 Surgery
  • 6.4 Enzyme Injection
  • 6.5 Radiation Therapy
  • 6.6 Steroid Shot
  • 6.7 Occupational Therapy
  • 6.8 Other Treatments

7 Global Dupuytren Disease Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 X-Ray
  • 7.3 Physical Examination
  • 7.4 Other Diagnosis

8 Global Dupuytren Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Oral
  • 8.4 Other Route Of Administrations

9 Global Dupuytren Disease Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy
  • 9.4 Other Distribution Channels

10 Global Dupuytren Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospitals
  • 10.4 Academic & Research Institutes

11 Global Dupuytren Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc
  • 13.2 AstraZeneca
  • 13.3 Endo International plc
  • 13.4 LEO Pharma A/S
  • 13.5 Spear Pharmaceuticals
  • 13.6 Hikma Pharmaceuticals PLC
  • 13.7 Bristol-Meyers Squibb Company
  • 13.8 Fresenius Kabi AG
  • 13.9 GSK plc
  • 13.10 Actiza Pharmaceutical Private Limited
  • 13.11 Nantong Jinghua Pharmaceutical Co., Ltd
  • 13.12 Novartis AG
  • 13.13 Bayer AG.
  • 13.14 Johnson & Johnson Services Ltd.
  • 13.15 Aurobindo Pharma

List of Tables

  • Table 1 Global Dupuytren Disease Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dupuytren Disease Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Dupuytren Disease Market Outlook, By Type I (2021-2030) ($MN)
  • Table 4 Global Dupuytren Disease Market Outlook, By Type II (2021-2030) ($MN)
  • Table 5 Global Dupuytren Disease Market Outlook, By Type III (2021-2030) ($MN)
  • Table 6 Global Dupuytren Disease Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 7 Global Dupuytren Disease Market Outlook, By Needle Aponeurotomy (2021-2030) ($MN)
  • Table 8 Global Dupuytren Disease Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 9 Global Dupuytren Disease Market Outlook, By Enzyme Injection (2021-2030) ($MN)
  • Table 10 Global Dupuytren Disease Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 11 Global Dupuytren Disease Market Outlook, By Steroid Shot (2021-2030) ($MN)
  • Table 12 Global Dupuytren Disease Market Outlook, By Occupational Therapy (2021-2030) ($MN)
  • Table 13 Global Dupuytren Disease Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 14 Global Dupuytren Disease Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 15 Global Dupuytren Disease Market Outlook, By X-Ray (2021-2030) ($MN)
  • Table 16 Global Dupuytren Disease Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 17 Global Dupuytren Disease Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 18 Global Dupuytren Disease Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Dupuytren Disease Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 20 Global Dupuytren Disease Market Outlook, By Oral (2021-2030) ($MN)
  • Table 21 Global Dupuytren Disease Market Outlook, By Other Route Of Administrations (2021-2030) ($MN)
  • Table 22 Global Dupuytren Disease Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Dupuytren Disease Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 24 Global Dupuytren Disease Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 25 Global Dupuytren Disease Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 26 Global Dupuytren Disease Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Dupuytren Disease Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 Global Dupuytren Disease Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Dupuytren Disease Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.